A company named Neuraltus Pharmaceuticals created a drug named NP001. NP001, a pH-adjusted IV formulation of purified sodium chlorite, is a novel molecule that regulates inflammation in vitro and in vivo.
It was used in a phase II clinical trial for ALS, and a subset of patients did not have any progression during the 6 month trial [0]. Something highly improbable.
Unfortunately this was not confirmed in a following phase III trial.